NRAS MUTATION CODON 12,13 & 61
MRP - ₹ 6,700
What is a NRAS MUTATION CODON 12,13 & 61?
The NRAS Mutation Codon 12, 13 & 61 test is a molecular diagnostic test that detects mutations in the NRAS gene, commonly associated with certain cancers such as melanoma, colorectal cancer, and acute myeloid leukemia. These mutations can drive abnormal cell growth and influence treatment response. The test is performed to identify the presence of NRAS mutations, guide targeted therapy decisions, and help doctors personalize cancer management by predicting prognosis and treatment effectiveness.
Additional Information
| Also known as/ Other names: | NRAS Mutation Analysis, NRAS Codon 12/13/61 Mutation Test, NRAS Gene Mutation Panel, NRAS Molecular Mutation Testing |
| Parameters: | 1 |
| Recommended for: | M/F/Others |
| Sample Type: | FFPE Tissue block |
| Patient Preparation: | No prior preparation is needed |
| Reports: | 5 days |
FAQs
It helps identify genetic mutations driving cancer growth, guiding targeted therapy decisions and predicting treatment response.
Patients diagnosed with melanoma, colorectal cancer, or acute myeloid leukemia may be recommended for testing.
A positive result indicates NRAS mutations, which may influence treatment planning and prognosis.
A negative result suggests no detectable NRAS mutations in the tested codons.
No, medications do not interfere with genetic mutation detection.
Without testing, treatment may not be personalized, reducing effectiveness in managing cancer.
It is usually done once per cancer diagnosis, unless new tissue samples are needed.
No, they are genetic changes, but early detection helps guide treatment.